Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.127
Peer-review started: May 1, 2015
First decision: May 18, 2015
Revised: June 10, 2015
Accepted: September 14, 2015
Article in press: September 15, 2015
Published online: November 6, 2015
Processing time: 199 Days and 8.7 Hours
The presence of concomitant diseases is an independent predictive factor for non-Helicobacter pylori (H. pylori) peptic ulcers. Patients contracting concomitant diseases have an increased risk of developing ulcer disease through pathogenic mechanisms distinct from those of H. pylori infections. Factors other than H. pylori seem critical in peptic ulcer recurrence in end stage renal disease (ESRD) and cirrhotic patients. However, early H. pylori eradication is associated with a reduced risk of recurrent complicated peptic ulcers in patients with ESRD and liver cirrhosis. Resistances to triple therapy are currently detected using culture-based and molecular methods. Culture susceptibility testing before first- or second-line therapy is unadvisable. Using highly effective empiric first-line and rescue regimens can yield acceptable results. Sequential therapy has been included in a recent consensus report as a valid first-line option for eradicating H. pylori in geographic regions with high clarithromycin resistance. Two novel eradication regimens, namely concomitant and hybrid therapy, have proven more effective in patients with dual- (clarithromycin- and metronidazole-) resistant H. pylori strains. We aim to review the prevalence of and eradication therapy for H. pylori infection in patients with ESRD and cirrhosis. Moreover, we summarized the updated H. pylori eradication regimens.
Core tip: The authors outline that patients contracting concomitant diseases have an increased risk of developing ulcer disease through pathogenic mechanisms distinct from those of Helicobacter pylori (H. pylori) infections. Early H. pylori eradication is associated with a reduced risk of recurrent complicated peptic ulcers in patients with end stage renal disease and liver cirrhosis. Two novel eradication regimens, namely concomitant and hybrid therapy, have proven more effective in patients with dual resistant H. pylori strains. High-dose amoxicillin therapy is promising and superior to standard regimens. Finally, culture and susceptibility testing should be performed before third-line treatment.
-
Citation: Chang SS, Hu HY.
Helicobacter pylori : Effect of coexisting diseases and update on treatment regimens. World J Gastrointest Pharmacol Ther 2015; 6(4): 127-136 - URL: https://www.wjgnet.com/2150-5349/full/v6/i4/127.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v6.i4.127
Helicobacter pylori (H. pylori), a widespread human pathogen affecting more than 50% of the human population[1], has been implicated in the development of peptic ulcer disease (PUD), gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma[2-4]. Hopkins et al[5] reported that the recurrence of peptic ulcers can markedly decrease from 70% to 10% or lower following H. pylori eradication.
Interactions among hosts, pathogens, and environmental factors are crucial to H. pylori colonization[6,7]. The presence of concomitant diseases is an independent predictive factor for non-H. pylori peptic ulcers[8]. Patients contracting concomitant diseases have an increased risk of developing ulcer disease through pathogenic mechanisms distinct from those of H. pylori infections[9,10]. Another explanation for the reported association between concomitant diseases and H. pylori-negative peptic ulcers is that many patients with comorbid conditions require nonsteroidal antiinflammatory drugs (NSAIDs). Whether H. pylori eradication can protect all patients with concomitant diseases, such as end-stage renal disease (ESRD) and liver cirrhosis, from ulcer recurrence requires further exploration.
Triple therapy is one of the oldest methods for H. pylori eradication. Resistances to triple therapy are currently detected using culture-based and molecular methods. However, such methods are difficult to apply in clinical practice because of the long period necessary before obtaining results as well as the high costs of routine performance. No therapy regimen can cure H. pylori infections in all treated patients, and some patients remain infected despite several consecutive standard therapies[11]. Concomitant therapy is a combination of antibiotics, including amoxicillin, metronidazole, clarithromycin, and a proton pump inhibitor (PPI), for a period of 5-7 d. This is a novel regimen, regarding which only a few evaluation studies have been published. Thus, the optimal therapy duration and success rates in populations with high dual resistance remain undefined.
Studies on H. pylori infections in uremic patients have reported rates varying from 27% to 73.0%[12-20]. This variation may have been caused by small sample sizes, nonuniform duration of dialysis, and varying methodologies and enrollment criteria. The H. pylori infection rate is lower in chronic kidney disease (CKD) (58.52%) and ESRD (56.25%) patients with PUD than in PUD patients without CKD, according to a Taiwanese population-based study[21]. Sugimoto et al[20] reported an H. pylori infection rate of 38.3% in patients with ESRD receiving dialysis for 4 years, suggesting that longer durations of dialysis reduce the risk of H. pylori infection. Factors other than H. pylori seem critical to peptic ulcer recurrence in patients with ESRD patients. These results imply that the diverse gastric environment of ESRD patients. Factors such as reductions in mucosa prostaglandin[12], hypergastrinemia[22], drugs such as NSAIDs[23], and systemic and local circulatory failure[20] influence the onset of recurrent PUD in patients with ESRD.
Invasive and noninvasive methods are available to detect H. pylori infections. However, dialyzed patients are often reluctant to undergo invasive procedures such as endoscopies[24]. Because patients with ESRD receive antisecretory drugs and require multiple antibiotic treatments for septic complications, inadvertent eradication of H. pylori infections is possible. Therefore, many H. pylori-negative patients with positive serologies were previously infected with H. pylori and inadvertently cured. The 2007 Maastricht Consensus Report on the diagnosis and treatment of H. pylori infections does not recommend the serological determination of H. pylori infections in routine clinical practice[25]. Huang et al[26] proposed that the diagnostic accuracy of H. pylori detection in patients with ESRD can be improved by performing the 13C-urea breath test (UBT) after hemodialysis therapy and assessing the UBT with a cutoff excess 13CO2/12CO2 ratio value exceeding 5. However, the diagnostic efficacy of the UBT for patients with ESRD remains less accurate than that for dyspeptic patients without renal impairment.
The UBT seems to be the most reliable diagnostic method for H. pylori infections in patients with chronic renal failure (CRF), and stool antigen tests show heterogeneous results, with substantial differences among manufacturers[24]. However, Wang et al[27] proposed that stool antigen is a noninvasive and reliable tool for screening H. pylori infections before therapy and assessing the success of eradication therapy in patients with ESRD. Establishing the reliability of diagnostic methods for H. pylori is crucial for managing infection[28]. Patients contracting CRF often have reduced gastric acid secretion and increased levels of urea in the blood and gastric juices[29-31], which may affect the density and distribution of H. pylori infections and, consequently, the reliability of diagnostic tests. Because no diagnostic tests for H. pylori infections are 100% reliable, the European Helicobacter pylori Study Group guidelines[32] recommend determining a gold standard from at least two techniques. The approach of combining all techniques has been used in previous studies evaluating the methods of diagnosing H. pylori infections[24,33,34]. However, this approach is too costly for use in clinical practice.
The optimal therapeutic regimen for H. pylori infection remains undefined in patients with ESRD. Few studies concerning triple therapy in uremic patients have been reported[27,35-39]. A 1-wk course of PPI-based triple therapy (omeprazole, 20 mg twice daily; amoxicillin, 1 g twice daily; and clarithromycin, 500 mg twice daily) achieved a high eradication rate of H. pylori infection in patients with CRF and a creatinine clearance (CrCl) of less than 30 mL/min per 1.73 m2, similar to that of controls with normal renal function[35]. The regimen was tolerated favorably. Another study showed that 7-d triple therapy with a low-dose OAC (omeprazole, 40 mg daily; amoxicillin, 500 mg daily; and clarithromycin, 500 mg daily) regimen was effective and safe for eradicating H. pylori infections in hemodialysis patients[40].
Amoxicillin[41] and clarithromycin[42], which are primarily eliminated renally, necessitate dosage reduction in patients with renal impairment according to CrCl. Wang et al[27] used 7-d triple therapy with omeprazole (20 mg twice daily), amoxicillin (1 g twice daily), and clarithromycin (500 mg twice daily) and reported an eradication rate of 86.8% among 40 hemodialysis patients. Tsukada et al[38] reported an eradication rate of 82.0% among 39 hemodialysis patients using 7-d triple therapy with omeprazole (30 mg twice daily), amoxicillin (500 mg twice daily), and clarithromycin (400 mg twice daily). Itatsu et al[39] used 7-d triple therapy with lansoprazole (30 mg twice daily), amoxicillin (375 mg twice daily), and clarithromycin (200 mg twice daily) in 11 hemodialysis patients and achieved an eradication rate of 72.7%.
Ideal treatment regimens should be effective, simple, and safe with fewer adverse effects and high patient compliance. One of the main reasons for treatment failure is irregular therapy with low compliance[43]. The prevalence of resistance to antibiotics, particularly clarithromycin and nitroimidazoles varies with gender, ethnic group and country[44]. Resistance to amoxicillin does not appear to be a critical problem in H. pylori-infected ESRD and non-ESRD patients in Turkey. By contrast, rates of resistance to clarithromycin are high, particularly in the ESRD population[45]. Prospective studies on the optimal therapy protocol, including antibiotic combination, dosage, and duration, in ESRD patients are warranted.
Patients with ESRD receiving hemodialysis often have various gastrointestinal (GI) problems such as nausea, dyspepsia, appetite loss, epigastric discomfort, and heartburn. Patients with ESRD exhibit a higher incidence of PUD than do patients without renal disease[12]. H. pylori is critical in the development of peptic ulcers[46]. Therefore, physicians must consider these two factors when treating ESRD in patients with upper GI disease.
ESRD is associated with a substantial health care burden in hospitalized patients with peptic ulcer bleeding (PUB). The presence of ESRD contributes to a higher mortality rate, longer hospital stay, and increased need for surgery among such patients[47]. A population-based study conducted in Taiwan[48] over a 10-year period revealed that PUD incidence was 10-12 times higher in patients with CKD than in those without CKD. Luo et al[49] reported that patients with ESRD receiving hemodialysis exhibited a high risk of PUB. Another study showed that patients with ESRD had a higher long-term risk of peptic ulcer rebleeding[50]. A crucial question is whether H. pylori eradication therapy is necessary for H. pylori-infected dialysis patients. Although H. pylori eradication is unequivocally effective in preventing peptic ulcer recurrence in the general population[3], such effectiveness has not been established in patients with ESRD. Tseng et al[12] conducted a prospective study in a single hospital and reported that H. pylori eradication in patients with ESRD reduces recurrent PUD. In addition, a higher recurrent peptic ulcer rate was noted after successful H. pylori eradication in H. pylori-infected ESRD patients. Sugimoto et al[20,51] reported that initiating hemodialysis treatment triggers a decrease in the prevalence of H. pylori infection. Moreover, receiving a maximum of 4 years of dialysis treatment has naturally cured H. pylori infection, thus supporting the practice of administering eradication therapy to H. pylori-infected dialysis patients, particularly those receiving dialysis for 5 years or more. However, a population-based study in Taiwan[52] revealed that early H. pylori eradication is associated with a reduced risk of recurrent complicated peptic ulcers in patients with ESRD; the authors recommended administering H. pylori eradication within 120 d after peptic ulcer diagnosis in H. pylori-infected ESRD patients who have developed peptic ulcers.
Cirrhotic patients with PUB have a 5-fold higher risk of complications or death[53]. H. pylori infection promotes the production of ammonia, which is an etiological factor involved in gastric mucosa disorders[54]. However, decompensated liver cirrhosis also involves hepatic encephalopathy because of higher serum ammonia levels. Thus, decompensated cirrhotic patients with H. pylori infections seem to have a higher risk of gastric mucosa lesions and GI complications.
Kim et al[55] revealed that H. pylori infection in cirrhotic patients may be inversely related to the severity of liver cirrhosis (Child-Pugh class A group: 51.5%, class B group: 30.5%, and class C group: 20%). Jung et al[56] also showed that the H. pylori infection rate is approximately 71.1% (162 of 228 patients) in all cirrhotic patients with peptic ulcers; however, the rate is only 50.0% (17 of 34 patients) in the Child-Pugh class C group. By contrast, Siringo et al[57] used serum anti-H. pylori IgG antibody levels to confirm a higher H. pylori infection rate of 76.5% in cirrhotic patients and 95.1% in cirrhotic patients with peptic ulcers. Such variability is likely explained by differences in H. pylori prevalence inherent in different populations and methodological differences among studies, including the means of testing used to define the presence of infection.
Bhargava et al[58] showed that gastric mucosa from patients with portal hypertension exhibited typical vascular dilatation and congestion, whereas the H. pylori infection rate was significantly lower in patients with portal hypertension (51.5% H. pylori infection rate) with particularly marked vascular dilatation (only 18.8% H. pylori infection rate) compared with the controls (75.5% H. pylori infection rate). Factors other than H. pylori seem critical in peptic ulcer recurrence in cirrhotic patients. In addition, H. pylori is not the predominant etiology for liver cirrhosis, particularly the decompensated type, with PUD or recurrent ulcer disease, according to a population-based study conducted in Taiwan[59]. This is consistent with previous studies[55,60,61], and a 35.6% to 51.92% H. pylori infection rate in cirrhotic patients with peptic ulcers.
The prevalence of H. pylori in patients with cirrhosis and PUD is generally less than 60%[60,62-65], suggesting that the pathogenesis of ulcer disease in a substantial proportion of cirrhotic patients may not be related to H. pylori infection[66-69]. Host environments are crucial to H. pylori colonization[7,70]. H. pylori adapts to humans, colonizing in children and remaining persistent throughout life[71]. The pathogenesis of the high peptic ulcer rate in cirrhotic patients is multifactorial. Cirrhotic patients have a higher risk of gastric mucosa damage because of reduced mucosal prostaglandin, which is crucial in the cytoprotection of gastric mucosa, which causes PUD. Other factors including increased serum gastrin concentration[72], impaired mucus secretion[73], and portal hypertensive gastropathy[74,75] may contribute to peptic ulcers and peptic ulcer recurrence in cirrhotic patients.
Compared with the general population, patients with cirrhosis have greater bleeding complications, delayed healing, and higher ulcer recurrence rates[68]. Luo et al[76] proposed that the risk of developing PUB in liver cirrhosis patients is 4-fold. A group of researchers from Taiwan found that 21 (58%) patients in whom H. pylori infections were eradicated developed recurrent duodenal ulcers within a year[60]. These results suggest that the pathogenesis of ulcer disease in a substantial proportion of patients with cirrhosis may not be related to H. pylori infection, a possibility proposed by researchers[65,67]. However, early H. pylori eradication is associated with a lower risk of recurrent peptic ulcers in cirrhotic patients, according to a Taiwan population-based study[77]. H. pylori eradication therapy is the primary method of treating cirrhotic patients with peptic ulcers.
A meta-analysis showed that H. pylori infections are associated with elevated blood ammonia levels in cirrhotic patients. In addition, the association seems more prominent in Asian patients than in Caucasian patients[78]. Addressing whether H. pylori eradication may benefit the long-term management of hepatic encephalopathy. Some studies have shown the benefit of eradication therapy[79-81]; however, other studies have reported negative results[82-84].
An ideal study protocol should also address a homogenous study population according to the severity of liver cirrhosis, assessment of psychometric tests, and measurements of ammonia levels in the blood. Currently, the demonstrated beneficial effect of eradication therapy in H. pylori-positive cirrhotic patients is insufficient for recommending the use of this therapy in clinical practice. An appropriately randomized study designed to assess the influence of H. pylori eradication on hepatic encephalopathy in cirrhotic patients is warranted.
Bile-tolerant helicobacter species such as H. hepaticus and H. bilis have frequently been reported to cause hepatitis in mice and other rodents[85]. The most comprehensively studied member of this group of enterohepatic Helicobacter species is H. hepaticus[86]. H. bilis has been found in species of inbred mice and reported to induce chronic hepatitis and hepatocellular carcinomas[87]. H. hepaticus was initially detected by immunofluorescence, electron microscopy, and culture in the livers of certain inbred mice and has been shown to cause multifocal necrotizing hepatitis, hepatic adenomas, and hepatocellular carcinomas[88,89]. The reason for further study of the possible role of these new helicobacter species in human liver disease has been to develop noninvasive serological assays for determining the seroprevalence of hepatic helicobacter infections[85].
Fox et al[90] stated that H. hepaticus infection increased the risk of liver cancer in hepatitis C virus and/or Hepatitis B virus infection. Fukuda et al[91] revealed that serum anti-H. hepaticus and/or anti-H. bilis antibody levels were significantly higher in patients with liver disease that in patients with other autoimmune hepatitis. Liver cirrhosis patients exhibited a substantially higher anti-H. hepaticus serum antibody level than other liver disease and health donors[92]. Although Helicobacter spp. have been identified in the liver of humans, their pathogenic role in human liver diseases remains largely unclear[93]. Kleine et al[94] established an in vitro model for demonstrating the pathogenic effect of a Helicobacter spp. on human liver cells, resulting in an inflammatory response with increased synthesis of inflammatory mediators and consecutive monocyte activation. The higher prevalence of Helicobacter spp. associated with more advanced stages of liver disease supports the possibility of their role in the progression of chronic hepatitis toward cirrhosis and hepatocellular carcinoma. An interventional study aimed at eradicating Helicobacter spp. from the liver would elucidate this association between Helicobacter spp. and liver cirrhosis and is thus warranted[93].
Successful eradication of H. pylori is a major component in treating these conditions[95]. However, the rate of H. pylori eradication after triple therapy is decreasing, with standard amoxicillin plus clarithromycin-based triple therapy achieving eradication rates of only approximately 75% in many series[96,97]. Apart from the conventional first-line regimen (triple therapy), other therapies have been proposed (sequential, concomitant, quadruple, and miscellaneous) to face the growing problem of antibiotic resistance. Although unsuccessful eradication can be caused by increasing antimicrobial resistance, an additional critical contributor is the treatment-related side effects and resultant incomplete therapy. New treatment regimens for H. pylori infections should be optimized to achieve an eradication rate of ≥ 95%[98]. Patient allergies and the local availability of drugs should be considered when selecting a treatment. H. pylori eradication should be confirmed after treatment, and, if second-line therapy is required, clarithromycin or a fluoroquinolone should not be reused[99].
First developed in Italy in the 1990s, sequential therapy (5-d PPI and amoxicillin, followed by 5-d PPI, clarithromycin, and metronidazole), is a regimen that has proven more effective in eradicating H. pylori than has triple therapy in many studies[100-104]. Recent multicenter randomized trials conducted in Taiwan have shown the superiority of sequential therapy over standard triple therapy. These findings also support that the most effective eradication regimen should be chosen on the basis of the prevalence of antibiotic-resistant H. pylori in a region[105]. The ability of sequential therapy to eradicate clarithromycin-resistant bacteria has been demonstrated, and sequential therapy has been included in a recent consensus report as a valid first-line option for eradicating H. pylori in geographic regions with high clarithromycin resistance[106].
Two novel eradication regimens, namely concomitant and hybrid therapy, have proven more effective than triple and sequential therapy in the last few years, particularly in patients with dual- (clarithromycin- and metronidazole-) resistant H. pylori strains[107-111]. Meta-analyses have shown that the outcome of concomitant therapy is duration-dependent[112]. Molina-Infante et al[113] proposed that optimized nonbismuth quadruple hybrid (consisting of omeprazole 40 mg twice daily and amoxicillin 1 g twice daily for 14 d, plus clarithromycin 500 mg twice daily and nitroimidazole 500 mg twice daily for the final 7 d as a quadruple therapy) and concomitant (consisting of omeprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and nitroimidazole 500 mg twice daily, all concurrently for 14 d) therapies cured more than 90% of patients with H. pylori infections in areas of high clarithromycin and metronidazole resistance. In concomitant therapy, all four drugs are administered for the entire therapy duration, indicating that this regimen is less complex than sequential therapy because it does not involve changing the number or type of drugs halfway through the therapy. A recently proposed hybrid therapy has proven as effective as a 14-d concomitant regimen in a pilot study[106].
The efficacy of treatment for H. pylori infection has decreased steadily because of increasing resistance to clarithromycin, metronidazole, and levofloxacin. Resistance to amoxicillin is generally low, and high intragastric pH increases the efficacy of amoxicillin. Therefore, Yang et al[114] proposed that a combination of a high-dose PPI and amoxicillin (dual therapy), consisting of rabeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 d, is superior to standard regimens as empirical first-line or rescue therapies for H. pylori infection and has similar safety profiles and tolerability.
During the initial development of bismuth quadruple therapy, the dose and duration of bismuth therapy were shown to be crucial variables, particularly in regions where metronidazole resistance was common[115]. However, many studies on these regimens have used suboptimal doses and durations of bismuth therapy, producing relatively poor results[116]. Bismuth-containing quadruple therapy is an alternative to standard triple therapy in areas with low clarithromycin resistance and the main first-line therapeutic option in areas with high prevalence of clarithromycin resistance. Using this regimen at full doses for 14 d produces a 95% or greater treatment success rate, irrespective of the level of metronidazole resistance[117].
Tailored antimicrobial therapy for an infectious disease is typically selected on the basis of susceptibility testing[99,118]. The treatment of H. pylori infection differs from that of most common infectious diseases because culture and susceptibility testing is generally not offered for H. pylori infections by hospital laboratories. In addition, many H. pylori infections can be identified using noninvasive testing (such as UBT or stool antigen testing), indicating that endoscopies are neither necessary nor acceptable to patients, and clinicians must choose treatment empirically. Therefore, culture and susceptibility testing should be performed before third-line treatment[106]. Salvage therapy (after multiple treatment failures) should be chosen on the basis of susceptibility testing whenever possible[101].
Song et al[119] proposed that supplementation with Saccharomyces boulardii could be effective for improving H. pylori eradication rates by reducing side effects, thus facilitating completion of eradication therapy. Probiotics are mostly administered by modulating the balance of its microflora[120]. Probiotic adjunct therapy is particularly useful in patients with a history of GI intolerance to antibiotic treatment[121]. These effects have been demonstrated for several species of probiotics, including Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus rhamnosus, and Bifidobacterium bifidum, among others[122-124]. Proposed mechanisms include modulating the colonization of the gastric mucosa and the direct killing of H. pylori through secreted metabolites with antimicrobial properties[95]. The lack of protocol standardization is problematic, and interpreting the various results is difficult.
Although other factors influence the onset of peptic ulcer and recurrent peptic ulcer in ESRD and cirrhotic patients, H. pylori eradication therapy is the primary method of treating ESRD and cirrhotic patients with peptic ulcers. Culture susceptibility testing before first- or second-line therapy is unadvisable. The known obstacles to culture susceptibility testing include the need for endoscopic examination and the fact that culture is time-consuming, costly, and not 100% sensitive. Using highly effective empiric first-line and rescue regimens can yield acceptable results[100,107,125]. In the near future, in vivo and in vitro studies may possibly be grouped according to geographic area to identify the most effective therapy for eradicating H. pylori, which relates to the local habitat.
We wish to thank the Taiwan Ministry of Education for their support for this work through its “Aim for the Top University Plan”.
P- Reviewer: Pellicano R, Vorobjova T, Vermi W
S- Editor: Yu J L- Editor: A E- Editor: Li D
1. | Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-1186. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1848] [Cited by in F6Publishing: 1836] [Article Influence: 83.5] [Reference Citation Analysis (3)] |
2. | Thiede C, Morgner A, Alpen B, Wündisch T, Herrmann J, Ritter M, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A. What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma. Gastroenterology. 1997;113:S61-S64. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
3. | Van der Hulst RW, Rauws EA, Köycü B, Keller JJ, Bruno MJ, Tijssen JG, Tytgat GN. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology. 1997;113:1082-1086. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 147] [Cited by in F6Publishing: 138] [Article Influence: 5.1] [Reference Citation Analysis (0)] |
4. | Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
5. | Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244-1252. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 373] [Cited by in F6Publishing: 387] [Article Influence: 13.8] [Reference Citation Analysis (0)] |
6. | Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008;134:306-323. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 379] [Cited by in F6Publishing: 370] [Article Influence: 23.1] [Reference Citation Analysis (0)] |
7. | Wu MS, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1878-1882. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
8. | Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther. 2009;30:791-815. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis (0)] |
9. | Xia HH, Phung N, Kalantar JS, Talley NJ. Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease. Med J Aust. 2000;173:515-519. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
10. | Shahin WA, Abdel-Baset EZ, Nassar AK, Atta MM, Kabil SM, Murray JA. Low incidence of Helicobacter pylori infection in patients with duodenal ulcer and chronic liver disease. Scand J Gastroenterol. 2001;36:479-484. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
11. | Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography. World J Gastroenterol. 2013;19:8168-8180. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 78] [Article Influence: 7.1] [Reference Citation Analysis (0)] |
12. | Tseng GY, Lin HJ, Fang CT, Yang HB, Tseng GC, Wang PC, Hung TL, Deng YC, Cheng YT, Huang CH. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. Aliment Pharmacol Ther. 2007;26:925-933. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
13. | Kang JY, Ho KY, Yeoh KG, Guan R, Wee A, Lee E, Lye WC, Leong SO, Tan CC. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. J Gastroenterol Hepatol. 1999;14:771-778. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
14. | Sotoudehmanesh R, Ali Asgari A, Ansari R, Nouraie M. Endoscopic findings in end-stage renal disease. Endoscopy. 2003;35:502-505. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 2.1] [Reference Citation Analysis (0)] |
15. | Loffeld RJ, Peltenburg HG, vd Oever H, Stobberingh E. Prevalence of Helicobacter pylori antibodies in patients on chronic intermittent haemodialysis. Nephron. 1991;59:250-253. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
16. | Davenport A, Shallcross TM, Crabtree JE, Davison AM, Will EJ, Heatley RV. Prevalence of Helicobacter pylori in patients with end-stage renal failure and renal transplant recipients. Nephron. 1991;59:597-601. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
17. | Luzza F, Imeneo M, Maletta M, Mantelli I, Tancre D, Merando G, Biancone L, Pallone F. Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology. Nephrol Dial Transplant. 1996;11:120-124. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
18. | Jaspersen D, Fassbinder W, Heinkele P, Kronsbein H, Schorr W, Raschka C, Brennenstuhl M. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol. 1995;30:585-588. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
19. | Khedmat H, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, Naseri MH, Davoudi F. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc. 2007;39:1003-1007. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis (0)] |
20. | Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 2009;75:96-103. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
21. | Chang SS, Hu HY. Lower Helicobacter pylori infection rate in chronic kidney disease and end-stage renal disease patients with peptic ulcer disease. J Chin Med Assoc. 2014;77:354-359. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
22. | Gür G, Boyacioglu S, Gül C, Turan M, Gürsoy M, Baysal C, Ozdemir N. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant. 1999;14:2688-2691. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
23. | Tseng GY, Lin HJ. Aspirin prescription and outcomes in hemodialysis patients. Am J Kidney Dis. 2008;51:1070-1071; author reply 1071. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
24. | López T, Quesada M, Almirall J, Sanfeliu I, Segura F, Calvet X. Usefulness of non-invasive tests for diagnosing Helicobacter pylori infection in patients undergoing dialysis for chronic renal failure. Helicobacter. 2004;9:674-680. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
25. | Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1348] [Cited by in F6Publishing: 1302] [Article Influence: 76.6] [Reference Citation Analysis (1)] |
26. | Huang JJ, Huang CJ, Ruaan MK, Chen KW, Yen TS, Sheu BS. Diagnostic efficacy of (13)C-urea breath test for Helicobacter pylori infection in hemodialysis patients. Am J Kidney Dis. 2000;36:124-129. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
27. | Wang YL, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. Am J Kidney Dis. 2001;38:98-103. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
28. | Chang SS, Hu HY. Reply. J Chin Med Assoc. 2014;77:657-658. [PubMed] [Cited in This Article: ] |
29. | Ala-Kaila K, Kataja M, Keyriläinen O, Pasternack A. The gastric secretion profile of patients with chronic renal failure. Ann Clin Res. 1981;13:65-70. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
30. | Ala-Kaila K. Gastric secretion kinetics in chronic renal failure. Scand J Gastroenterol. 1987;22:1185-1192. [PubMed] [Cited in This Article: ] |
31. | Kim H, Park C, Jang WI, Lee KH, Kwon SO, Robey-Cafferty SS, Ro JY, Lee YB. The gastric juice urea and ammonia levels in patients with Campylobacter pylori. Am J Clin Pathol. 1990;94:187-191. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
32. | Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut. 1997;41 Suppl 2:S1-S9. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
33. | Calvet X, Quesada M, Roselló M, Salceda F, Sanfeliu I, Dalmau B, Gil M. Stool antigen for the diagnosis of Helicobacter pylori infection in cirrhosis: comparative usefulness of three different methods. Aliment Pharmacol Ther. 2003;17:727-731. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
34. | Thijs JC, van Zwet AA, Thijs WJ, Oey HB, Karrenbeld A, Stellaard F, Luijt DS, Meyer BC, Kleibeuker JH. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol. 1996;91:2125-2129. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
35. | Mak SK, Loo CK, Wong AM, Wong PN, Lo KY, Tong GM, Lam EK, Wong AK. Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure. Am J Kidney Dis. 2002;40:576-581. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis (0)] |
36. | Tamura H, Tokushima H, Murakawa M, Matsumura O, Itoyama S, Sekine S, Hirose H, Mitarai T, Isoda K. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. Am J Kidney Dis. 1997;29:86-90. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis (0)] |
37. | Mak SK, Loo CK, Wong PN, Lo KY, Tong GM, Lam EK, Wong AK. A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure. Singapore Med J. 2003;44:74-78. [PubMed] [Cited in This Article: ] |
38. | Tsukada K, Miyazaki T, Katoh H, Masuda N, Ojima H, Fukai Y, Nakajima M, Manda R, Fukuchi M, Kuwano H. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients. Scand J Gastroenterol. 2002;37:1265-1268. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
39. | Itatsu T, Miwa H, Nagahara A, Kubota M, Miyazaki A, Sato N, Hayashida Y. Eradication of Helicobacter pylori in hemodialysis patients. Ren Fail. 2007;29:97-102. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
40. | Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, Jin CJ. Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. Clin Exp Nephrol. 2010;14:469-473. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
41. | Arancibia A, Drouguett MT, Fuentes G, González G, González C, Thambo S, Palombo G. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. Int J Clin Pharmacol Ther Toxicol. 1982;20:447-453. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
42. | Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:189-204. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 2.4] [Reference Citation Analysis (0)] |
43. | Wermeille J, Cunningham M, Dederding JP, Girard L, Baumann R, Zelger G, Buri P, Metry JM, Sitavanc R, Gallaz L. Failure of Helicobacter pylori eradication: is poor compliance the main cause. Gastroenterol Clin Biol. 2002;26:216-219. [PubMed] [Cited in This Article: ] |
44. | Harris A, Misiewicz JJ. Treating Helicobacter pylori--the best is yet to come. Gut. 1996;39:781-783. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
45. | Aydemir S, Boyacioglu S, Gur G, Demirbilek M, Can FK, Korkmaz M, Yilmaz U. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol. 2005;11:842-845. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
46. | McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010;362:1597-1604. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 529] [Cited by in F6Publishing: 529] [Article Influence: 37.8] [Reference Citation Analysis (0)] |
47. | Parasa S, Navaneethan U, Sridhar AR, Venkatesh PG, Olden K. End-stage renal disease is associated with worse outcomes in hospitalized patients with peptic ulcer bleeding. Gastrointest Endosc. 2013;77:609-616. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
48. | Liang CC, Muo CH, Wang IK, Chang CT, Chou CY, Liu JH, Yen TH, Huang CC, Chung CJ. Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications. PLoS One. 2014;9:e87952. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
49. | Luo JC, Leu HB, Huang KW, Huang CC, Hou MC, Lin HC, Lee FY, Lee SD. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ. 2011;183:E1345-E1351. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 6.2] [Reference Citation Analysis (0)] |
50. | Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut. 2011;60:1038-1042. [PubMed] [Cited in This Article: ] |
51. | Sugimoto M, Yamaoka Y. Review of Helicobacter pylori infection and chronic renal failure. Ther Apher Dial. 2011;15:1-9. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
52. | Chang SS, Hu HY. Association between early Helicobacter pylori eradication and a lower risk of recurrent complicated peptic ulcers in end-stage renal disease patients. Medicine (Baltimore). 2015;94:e370. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
53. | Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P. Epidemiology of peptic ulcer disease in cirrhotic patients: role of Helicobacter pylori infection. Am J Gastroenterol. 1998;93:2501-2507. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis (0)] |
54. | Tsujii M, Kawano S, Tsuji S, Fusamoto H, Kamada T, Sato N. Mechanism of gastric mucosal damage induced by ammonia. Gastroenterology. 1992;102:1881-1888. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis (0)] |
55. | Kim DJ, Kim HY, Kim SJ, Hahn TH, Jang MK, Baik GH, Kim JB, Park SH, Lee MS, Park CK. Helicobacter pylori infection and peptic ulcer disease in patients with liver cirrhosis. Korean J Intern Med. 2008;23:16-21. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
56. | Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, Park JJ, Lee HS, Chun HJ, Um SH. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis. 2009;41:134-140. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
57. | Siringo S, Vaira D, Menegatti M, Piscaglia F, Sofia S, Gaetani M, Miglioli M, Corinaldesi R, Bolondi L. High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Dig Dis Sci. 1997;42:2024-2030. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 66] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
58. | Bhargava N, Venkateswaran S, Ramakrishna BS, Mathan M. Colonization by Helicobacter pylori and its relationship to histological changes in the gastric mucosa in portal hypertension. J Gastroenterol Hepatol. 1994;9:507-511. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
59. | Chang SS, Hu HY. Helicobacter pylori is not the predominant etiology for liver cirrhosis patients with peptic ulcer disease. Eur J Gastroenterol Hepatol. 2013;25:159-165. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
60. | Lo GH, Yu HC, Chan YC, Chen WC, Hsu PI, Lin CK, Lai KH. The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc. 2005;62:350-356. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
61. | Wang CH, Ma LR, Lin RC, Kuo JY, Chang KK. Helicobacter pylori infection and risk of peptic ulcer among cirrhotic patients. J Formos Med Assoc. 1997;96:55-58. [PubMed] [Cited in This Article: ] |
62. | Chen LS, Lin HC, Lee FY, Hou MC, Lee SD. Prevalence of duodenal ulcer in cirrhotic patients and its relation to Helicobacter pylori and portal hypertension. Zhonghua Yixue Zazhi (Taipei). 1995;56:226-231. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
63. | Wu CS, Lin CY, Liaw YF. Helicobacter pylori in cirrhotic patients with peptic ulcer disease: a prospective, case controlled study. Gastrointest Endosc. 1995;42:424-427. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
64. | Dore MP, Mura D, Deledda S, Maragkoudakis E, Pironti A, Realdi G. Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis: the role of Helicobacter pylori infection and portal hypertensive gastropathy. Can J Gastroenterol. 2004;18:521-524. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
65. | Calvet X, Navarro M, Gil M, Mas P, Rivero E, Sanfeliu I, Brullet E, Campo R, Dalmau B, Lafont A. Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. J Hepatol. 1997;26:1249-1254. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
66. | Farinati F, De Bona M, Floreani A, Foschia F, Rugge M. Helicobacter pylori and the liver: any relationship. Ital J Gastroenterol Hepatol. 1998;30:124-128. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis (0)] |
67. | van Nieuwkerk CM, Kuipers EJ. Liver cirrhosis and peptic ulcer disease; a correlation with Helicobacter pylori. Neth J Med. 2000;56:203-205. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
68. | Saad RJ, Chey WD. Peptic ulcer disease in patients with chronic liver disease: looking beyond bugs and drugs. Gastrointest Endosc. 2005;62:357-359. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
69. | Gisbert JP, Moreno-Otero R, Pajares JM. [Prevalence of Helicobacter pylori infection in chronic liver disease and relationship with its complications: systematic review and meta-analysis]. Med Clin (Barc). 2002;119:464-474. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis (0)] |
70. | Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113:321-333. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 626] [Cited by in F6Publishing: 606] [Article Influence: 30.3] [Reference Citation Analysis (1)] |
71. | Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest. 2009;119:2475-2487. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 367] [Cited by in F6Publishing: 378] [Article Influence: 25.2] [Reference Citation Analysis (0)] |
72. | Furuta T, Baba S, Takashima M, Futami H, Arai H, Kajimura M, Hanai H, Kaneko E. Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol. 1998;33:357-363. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
73. | Suzuki H, Ishii H. [Peptic ulcer disease complicated with liver cirrhosis]. Nihon Rinsho. 2004;62:532-540. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
74. | Chen CT, Wang TF, Chan CC, Lee FY, Chang FY, Lin HC, Hou MC, Lu RH, Chu CJ, Wang SS. Role of chronic Helicobacter pylori infection in hyperdynamic circulation of cirrhotic patients. Hepatogastroenterology. 2002;49:208-212. [PubMed] [Cited in This Article: ] |
75. | Kitano S, Dolgor B. Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis. J Gastroenterol. 2000;35:79-86. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
76. | Luo JC, Leu HB, Hou MC, Huang CC, Lin HC, Lee FY, Chang FY, Chan WL, Lin SJ, Chen JW. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2012;36:542-550. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis (0)] |
77. | Chang SS, Hu HY. H. pylori eradication lower ulcers in cirrhosis. [Corrected]. J Dig Dis. 2014;15:451-458. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
78. | Jiang HX, Qin SY, Min ZG, Xie MZ, Lin T, Hu BL, Guo XY. Association of Helicobacter pylori with elevated blood ammonia levels in cirrhotic patients: a meta-analysis. Yonsei Med J. 2013;54:832-838. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
79. | Dasani BM, Sigal SH, Lieber CS. Analysis of risk factors for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol. 1998;93:726-731. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
80. | Miyaji H, Ito S, Azuma T, Ito Y, Yamazaki Y, Ohtaki Y, Sato F, Hirai M, Kuriyama M, Kohli Y. Effects of Helicobacter pylori eradication therapy on hyperammonaemia in patients with liver cirrhosis. Gut. 1997;40:726-730. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
81. | Agrawal A, Gupta A, Chandra M, Koowar S. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. Indian J Gastroenterol. 2011;30:29-32. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
82. | Miquel J, Barcena R, Boixeda D, Fernández J, SanRoman AL, Martín-de-Argila C, Ramosa F. Role of Helicobacter pylori infection and its eradication in patients with subclinical hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2001;13:1067-1072. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
83. | Scotiniotis IA, Lucey MR, Metz DC. Helicobacter pylori infection is not associated with subclinical hepatic encephalopathy in stable cirrhotic patients. Dig Dis Sci. 2001;46:2744-2751. [PubMed] [Cited in This Article: ] |
84. | Quero JC, Hartmann IJ, de Rooij F, Wilson JH, Schalm SW. Hyperammonaemia and Helicobacter pylori. Lancet. 1995;346:713-714. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
85. | Nilsson I, Lindgren S, Eriksson S, Wadström T. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease. Gut. 2000;46:410-414. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 2.4] [Reference Citation Analysis (0)] |
86. | Fox JG, Ge Z, Whary MT, Erdman SE, Horwitz BH. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol. 2011;4:22-30. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 135] [Cited by in F6Publishing: 139] [Article Influence: 10.7] [Reference Citation Analysis (0)] |
87. | Fox JG, Yan LL, Dewhirst FE, Paster BJ, Shames B, Murphy JC, Hayward A, Belcher JC, Mendes EN. Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice. J Clin Microbiol. 1995;33:445-454. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
88. | Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins MJ, Gorelick PL, Nagashima K, Gonda MA, Gilden RV. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst. 1994;86:1222-1227. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 299] [Cited by in F6Publishing: 273] [Article Influence: 9.1] [Reference Citation Analysis (0)] |
89. | Fox JG, Li X, Yan L, Cahill RJ, Hurley R, Lewis R, Murphy JC. Chronic proliferative hepatitis in A/JCr mice associated with persistent Helicobacter hepaticus infection: a model of helicobacter-induced carcinogenesis. Infect Immun. 1996;64:1548-1558. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
90. | Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JL, Doernte AL, Williams M, McFaline JL, Essigmann JM, Schauer DB. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut. 2010;59:88-97. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 181] [Cited by in F6Publishing: 176] [Article Influence: 12.6] [Reference Citation Analysis (0)] |
91. | Fukuda Y, Shimoyama T, Ohmura T, Sano Y, Nakabayashi N, Takahashi R, Fujioka T, Mitchell HM, Shimoyama T. Characterization and application of a new monoclonal antibody with high specificity for Helicobacter hepaticus. Helicobacter. 2009;14:66-71. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
92. | Murakami K, Takahashi R, Ono M, Watanabe K, Okimoto T, Kodama M, Abe D, Kimura M, Fujioka T. Serodiagnosis of Helicobacter hepaticus infection in patients with liver and gastrointestinal diseases: western blot analysis and ELISA using a highly specific monoclonal antibody for H. hepaticus antigen. J Gastroenterol. 2011;46:1120-1126. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
93. | Pellicano R, Ménard A, Rizzetto M, Mégraud F. Helicobacter species and liver diseases: association or causation. Lancet Infect Dis. 2008;8:254-260. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 6.6] [Reference Citation Analysis (0)] |
94. | Kleine M, Worbs T, Schrem H, Vondran FW, Kaltenborn A, Klempnauer J, Förster R, Josenhans C, Suerbaum S, Bektas H. Helicobacter hepaticus induces an inflammatory response in primary human hepatocytes. PLoS One. 2014;9:e99713. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
95. | Medeiros JA, Pereira MI. The use of probiotics in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:1-5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
96. | Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 2008;12:251-256. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
97. | de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 2007;102:951-956. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 87] [Cited by in F6Publishing: 92] [Article Influence: 5.4] [Reference Citation Analysis (0)] |
98. | O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PubMed] [Cited in This Article: ] |
99. | Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011;8:79-88. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 132] [Cited by in F6Publishing: 149] [Article Influence: 11.5] [Reference Citation Analysis (0)] |
100. | Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011;17:3971-3975. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 108] [Article Influence: 8.3] [Reference Citation Analysis (0)] |
101. | Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 1997;11:929-933. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
102. | Gisbert JP, Calvet X, O’Connor A, Mégraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313-325. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
103. | Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 184] [Cited by in F6Publishing: 186] [Article Influence: 16.9] [Reference Citation Analysis (95)] |
104. | Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs. 2013;73:815-824. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
105. | Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381:205-213. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 177] [Cited by in F6Publishing: 167] [Article Influence: 15.2] [Reference Citation Analysis (0)] |
106. | Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646-664. [PubMed] [Cited in This Article: ] |
107. | Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
108. | Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-145. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 125] [Cited by in F6Publishing: 142] [Article Influence: 10.9] [Reference Citation Analysis (0)] |
109. | Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter. 2013;18:129-134. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 7.5] [Reference Citation Analysis (0)] |
110. | Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter. 2012;17:269-276. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.2] [Reference Citation Analysis (0)] |
111. | Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18:459-467. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
112. | Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:109-118. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 155] [Cited by in F6Publishing: 170] [Article Influence: 11.3] [Reference Citation Analysis (0)] |
113. | Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121-128.e1. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 139] [Cited by in F6Publishing: 143] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
114. | Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895-905.e5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 114] [Cited by in F6Publishing: 142] [Article Influence: 15.8] [Reference Citation Analysis (0)] |
115. | van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol. 1999;94:1751-1759. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
116. | Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105:65-73. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 153] [Cited by in F6Publishing: 150] [Article Influence: 10.7] [Reference Citation Analysis (0)] |
117. | Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-807.e1. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 108] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
118. | Graham DY. Helicobacter pylori eradication therapy research: Ethical issues and description of results. Clin Gastroenterol Hepatol. 2010;8:1032-1036. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
119. | Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15:206-213. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis (0)] |
120. | Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365-378. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2563] [Cited by in F6Publishing: 1972] [Article Influence: 56.3] [Reference Citation Analysis (0)] |
121. | Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011;45:960-966. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
122. | Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97-107. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis (0)] |
123. | Canducci F, Cremonini F, Armuzzi A, Di Caro S, Gabrielli M, Santarelli L, Nista E, Lupascu A, De Martini D, Gasbarrini A. Probiotics and Helicobacter pylori eradication. Dig Liver Dis. 2002;34 Suppl 2:S81-S83. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
124. | Chenoll E, Casinos B, Bataller E, Astals P, Echevarría J, Iglesias JR, Balbarie P, Ramón D, Genovés S. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 2011;77:1335-1343. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis (0)] |
125. | Gisbert JP. Is culture necessary before first-line treatment for Helicobacter pylori infection. Intern Med. 2011;50:2717; author reply 2719-2720. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis (0)] |